Key Highlights

  • Loss per share was USD 0.13, matching an estimate of a USD 0.13 loss.
  • Net loss was USD 21.45 million, against USD 11.80 million a year earlier.
  • Research and development expenses were USD 19.06 million, against USD 10.09 million.
  • Cash and marketable securities were USD 299.4 million at September 30.

Trevi Therapeutics (NASDAQ:TRVI) reported a third quarter 2026 loss per share of USD 0.13, matching an estimate of a USD 0.13 loss and compared with a USD 0.08 loss in the third quarter of 2025. Net loss was USD 21.45 million, against USD 11.80 million.

The loss from operations was USD 24.49 million, compared with USD 13.92 million. Chief executive officer Jennifer Good led the third quarter Earnings Call and Business update.

Operating Expenses

Research and development expenses were USD 19.06 million, compared with USD 10.09 million. General and administrative expenses were USD 5.42 million, compared with USD 3.83 million, which the filing attributes primarily to an increase in stock-based compensation and personnel-related expenses from increased headcount.

Total operating expenses were USD 24.49 million, against USD 13.92 million. Other income, net, was USD 3.0 million, compared with USD 2.1 million, with interest income, net, of USD 3.02 million for the quarter.

Nine-Month Results

For the nine months ended September 30, 2026, net loss was USD 52.44 million, compared with USD 34.44 million. Total operating expenses were USD 59.91 million, against USD 39.11 million.

Research and development expenses for the nine months were USD 44.16 million, against USD 27.29 million, and general and administrative expenses were USD 15.75 million, against USD 11.82 million. Stock-based compensation within general and administrative expense was USD 5.22 million, against USD 2.18 million.

OCEAN Trials and Liquidity

On the call, management said the OCEAN trials are in early stages and progressing, and that it continues to believe it is on its previously stated guidance for OCEAN-2, a 12-week study reading out in the second half of 2027, and OCEAN-1, with a 24-week efficacy endpoint and 52 weeks of safety reading out in the first half of 2028. It said it plans to give an update once 50% of patients are randomized in each trial, and plans to initiate another trial in the first quarter of 2027.

Management also described an independent statistics team outside the company that is to review unblinded data once 50 patients complete the trial and confirm powering assumptions. The filing notes that nalbuphine has been approved and marketed as an injectable for pain indications for decades in the United States and Europe. As of September 30, 2026, the company had cash, cash equivalents and marketable securities of USD 299.4 million.

The filing also states that the company has entered into agreements with contract research organizations and contract Manufacturing organizations that provide services in connection with its Research and Development activities, and that the value of goods and services received in a reporting period is estimated based on the level of services performed and the progress of the studies.

Trevi Therapeutics Q3 2026 Earnings: Key Takeaways

Trevi Therapeutics reported a third quarter 2026 loss per share of USD 0.13 and a net loss of USD 21.45 million. Research and development expenses were USD 19.06 million, and cash, cash equivalents and marketable securities were USD 299.4 million.